Nov 4, 2022, 10:55 AM by

I wanted to share the Vermont Department of Health and VisualDx just launched the Clinician Support Initiative to help healthcare professionals respond to emergent infectious disease outbreaks, like Monkeypox, Covid, and Polio, by leveraging assistive technology. Given the challenge of identifying and treating rare diseases amid ongoing staffing and burnout issues, Vermont is offering all clinicians in the state free access to VisualDx’s diagnostic support platform. The tool contains clinical information, medical reference images, and real-time reporting, all of which are critical for patient care and public health response.

Nov 4, 2022, 10:53 AM by

medmix Drug Delivery (Haselmeier™) and AARDEX® Group Join Forces to Improve Self-Administration of Injectable Drugs in Clinical Trials. Liege, Belgium - November 3, 2022: medmix Drug Delivery (Haselmeier) and AARDEX Group announced today a collaboration, combining Haselmeier´s D-Flex™ Logbook with AARDEX Group’s Medication Adherence software and hardware ecosystem.

Nov 3, 2022, 10:59 AM by

Jumo Health, a global provider of age appropriate, culturally sensitive medical education resources, today announced it has been recognized by Inc. Magazine in its inaugural Power Partner Awards.

Nov 3, 2022, 10:58 AM by

Nov 3, 2022, 01:00 AM by User Not Found

Bio-IT World | The timing of age-associated vigorous movement cessation is highly correlated with lifespan across populations, but the reason may be some unknown upstream factor that throws into question the way biomarkers are sometimes used to track the benefits of anti-aging therapies. At least that’s what is suggested by a new study using a “Lifespan Machine” to follow the life and death of tens of thousands of nematodes.

Nov 2, 2022, 10:15 AM by

Vaxess Technologies, Inc., a life sciences company developing a shelf-stable, sustained-release vaccine patch, today announced the closing of its Series B funding.

Nov 2, 2022, 10:15 AM by

Nov 2, 2022, 10:14 AM by

Nov 2, 2022, 10:11 AM by

BOC Sciences declares that some of its peptide products have been proven applicable for osteoporosis treatment, which is a significant contribution to the therapeutic areas.

Nov 2, 2022, 10:11 AM by

Owing to the continuously upgraded synthesis technologies and analytical abilities, BOC Sciences has performed well in the polymer industry, serving the community with a comprehensive product portfolio and valuable technical support.

Nov 2, 2022, 10:10 AM by

BOC Sciences provides global customers with a range of high-quality stable isotope labeling compounds for biomedical research. It recently announced the availability of labeled carbohydrates, arousing an enthusiastic response from the market.

Nov 2, 2022, 10:10 AM by

BOC Sciences announces support for antibody-drug conjugate (ADC) development, registration, and release by providing comprehensive analysis and characterization technologies.

Nov 2, 2022, 10:09 AM by

Nov 2, 2022, 09:59 AM by

Nov 2, 2022, 09:58 AM by

Nov 2, 2022, 09:54 AM by

Nov 2, 2022, 01:00 AM by User Not Found

Bio-IT World | Best practice surveillance protocols for seven diseases caused by group A Streptococcus (strep A) were recently released, and public health researchers are now actively working to identify several key sentinel sites to implement them. Harmonizing case definitions and the surveillance methodologies is a key step in accelerating development of a safe, effective, and affordable strep A vaccine to prevent these diseases.

Nov 1, 2022, 10:38 AM by

BRIM Biotechnology, Inc. ("BRIM," TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. BRIM will submit the Phase 3 study protocol to the FDA in Q4 2022.

Nov 1, 2022, 10:37 AM by

Findings illustrate promise of technology to lower misdiagnosis rate for deadliest form of skin cancer

Nov 1, 2022, 10:28 AM by